It’s checkmate for Opdivo small-cell lung cancer trial
Bristol-Myers Squibb have recently announced the failure of the drug Opdivo® (nivolumab) to show a clinically significant effect in the treatment of small-cell lung cancer.
Browsing: drug development
CAR-T therapy Yescarta get EU green light but meets resistance from NICE
Yescarta®, a novel personalized CAR T cell therapy has been approved for use in Europe by the EMA but has received a draft negative guidance from NICE.
FDA approves first-in-class treatment for rare adrenal tumors
The US FDA has approved Progenics Pharmaceuticals’ Adzera®, a first-in-class treatment for two rare adrenal tumors: pheochromocytoma and paraganglioma.
ESMO WCGI: Trifluridine and tipiracil show promise as metastatic gastric cancer treatment in Phase III trial
Clinical data demonstrates improvement in metastatic gastric cancer patient overall survival in comparison with the placebo.
Tumor-like spheres used to screen for potential cancer drugs
A novel three-dimensional high-throughput screening approach allows researchers to identify inducers of a mutant KRAS selective lethal phenotype.
AstraZeneca releases ARCTIC third-line NSCLC trial results
AstraZeneca (DE, USA) and Medimmune (MD, USA), recently announced results from the ARCTIC trial in third-line non-small cell lung cancer (NSCLC).
Researchers uncover 80 potential ways of targeting prostate cancer
A study led by researchers at The Institute of Cancer Research (London, UK) has uncovered numerous ways of targeting prostate cancer.
Expanded access to cancer treatments with the biosimilar filgrastim-sndz
To mark World Health Day we spoke with Ivo Abraham from the University of Arizona (AZ, USA) about the role that biosimilars play in expanding access to cancer treatments, particularly in regards to the biosimilar filgrastim-sndz.
Increasing access to cancer medicines: what role do biosimilar medicines play?
In this interview find out what advancements have been made in the field of biosimilars and how they are helping improve access to cancer medicines.
Cyramza® meets primary endpoint of overall survival in liver cancer study
Eli Lilly have announced that Cyramza® has met its primary endpoint of overall survival, as well as its secondary goal of progression-free survival in late-stage liver cancer study.
